Equities research analysts expect NxStage Medical, Inc. (NASDAQ:NXTM) to report sales of $102.29 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for NxStage Medical’s earnings. The lowest sales estimate is $100.90 million and the highest is $103.60 million. NxStage Medical reported sales of $91.95 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.2%. The company is scheduled to announce its next quarterly earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that NxStage Medical will report full-year sales of $102.29 million for the current year, with estimates ranging from $398.30 million to $402.90 million. For the next year, analysts expect that the business will report sales of $443.89 million per share, with estimates ranging from $435.90 million to $460.20 million. Zacks’ sales averages are an average based on a survey of research firms that that provide coverage for NxStage Medical.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The company had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.03) earnings per share.

Several equities analysts have commented on NXTM shares. Craig Hallum downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Stephens downgraded shares of NxStage Medical from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $33.00 to $30.00 in a research report on Wednesday, August 9th. BidaskClub raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. Jefferies Group LLC downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and lowered their target price for the stock from $33.00 to $30.00 in a research report on Tuesday, August 8th. Finally, Zacks Investment Research downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Two analysts have rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. NxStage Medical currently has a consensus rating of “Hold” and a consensus target price of $30.25.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $27.56, for a total transaction of $27,560.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $29.21, for a total transaction of $102,235.00. Following the sale, the senior vice president now owns 16,270 shares of the company’s stock, valued at $475,246.70. The disclosure for this sale can be found here. Insiders have sold 50,400 shares of company stock valued at $1,406,020 over the last 90 days. Corporate insiders own 4.70% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in NXTM. Russell Investments Group Ltd. boosted its holdings in NxStage Medical by 67.9% during the first quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock valued at $773,000 after acquiring an additional 11,668 shares during the period. Bank of New York Mellon Corp boosted its holdings in NxStage Medical by 0.5% during the first quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock valued at $17,168,000 after acquiring an additional 2,914 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in NxStage Medical by 148.4% during the first quarter. UBS Asset Management Americas Inc. now owns 32,532 shares of the medical device company’s stock valued at $873,000 after acquiring an additional 19,434 shares during the period. Karp Capital Management Corp bought a new stake in NxStage Medical during the first quarter valued at about $256,000. Finally, Parametric Portfolio Associates LLC boosted its holdings in NxStage Medical by 45.9% during the first quarter. Parametric Portfolio Associates LLC now owns 45,716 shares of the medical device company’s stock valued at $1,227,000 after acquiring an additional 14,384 shares during the period. Institutional investors own 92.66% of the company’s stock.

Shares of NxStage Medical (NXTM) traded down 0.07% on Wednesday, hitting $27.52. The company’s stock had a trading volume of 356,720 shares. The stock’s market capitalization is $1.82 billion. NxStage Medical has a 52 week low of $20.45 and a 52 week high of $30.80. The stock’s 50 day moving average price is $27.77 and its 200 day moving average price is $25.84.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate NxStage Medical, Inc. (NXTM) Will Announce Quarterly Sales of $102.29 Million” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/11/zacks-brokerages-anticipate-nxstage-medical-inc-nxtm-will-announce-quarterly-sales-of-102-29-million.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.